Get a glimpse into our company and investor data—powered by the PitchBook Platform
Owner and operator of a pharmaceutical company. The company is engaged in providing services related to discovery, development, and delivery of chimeric antigen receptor (CAR) T-cell immunotherapies.
This information is reserved for PitchBook Platform users. To explore CARgenix Holdings‘s full profile, request access.
© 2019 PitchBook Data. All rights reserved. PitchBook is a financial technology company that provides data on the capital markets.